Targeting HER2 in prostate cancer: where to next? - PubMed (original) (raw)

Editorial

Targeting HER2 in prostate cancer: where to next?

David B Solit et al. J Clin Oncol. 2007.

No abstract available

PubMed Disclaimer

Comment in

• Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
  Menendez JA, Lupu R. Menendez JA, et al. J Clin Oncol. 2007 Jun 10;25(17):2496-8; author reply 2499. doi: 10.1200/JCO.2007.11.0395. J Clin Oncol. 2007. PMID: 17557968 No abstract available.

Comment on

• Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
  de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.

Similar articles

• HER2 in prostate cancer--a viable target or innocent bystander?
  Scher HI. Scher HI. J Natl Cancer Inst. 2000 Dec 6;92(23):1866-8. doi: 10.1093/jnci/92.23.1866. J Natl Cancer Inst. 2000. PMID: 11106669 Review. No abstract available.
• Update on HER-kinase-directed therapy in prostate cancer.
  Gross ME, Jo S, Agus DB. Gross ME, et al. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.
• Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
  Menendez JA, Lupu R. Menendez JA, et al. J Clin Oncol. 2007 Jun 10;25(17):2496-8; author reply 2499. doi: 10.1200/JCO.2007.11.0395. J Clin Oncol. 2007. PMID: 17557968 No abstract available.
• Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
  Carrión-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A. Carrión-Salip D, et al. Int J Oncol. 2012 Sep;41(3):1128-38. doi: 10.3892/ijo.2012.1509. Epub 2012 Jun 6. Int J Oncol. 2012. PMID: 22684500
• Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
  Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P, Almendro V. Mayordomo C, et al. J Cell Physiol. 2012 Apr;227(4):1358-66. doi: 10.1002/jcp.22848. J Cell Physiol. 2012. PMID: 21604273

Cited by

• Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
  Tsai YC, Zeng T, Abou-Kheir W, Yeh HL, Yin JJ, Lee YC, Chen WY, Liu YN. Tsai YC, et al. Mol Cancer. 2018 Feb 19;17(1):42. doi: 10.1186/s12943-018-0785-1. Mol Cancer. 2018. PMID: 29455655 Free PMC article.
• Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.
  Carlsson J, Shen L, Xiang J, Xu J, Wei Q. Carlsson J, et al. Oncol Lett. 2013 Jan;5(1):208-214. doi: 10.3892/ol.2012.996. Epub 2012 Oct 25. Oncol Lett. 2013. PMID: 23255921 Free PMC article.
• Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.
  Ljubimova JY, Fujita M, Ljubimov AV, Torchilin VP, Black KL, Holler E. Ljubimova JY, et al. Nanomedicine (Lond). 2008 Apr;3(2):247-65. doi: 10.2217/17435889.3.2.247. Nanomedicine (Lond). 2008. PMID: 18373429 Free PMC article. Review.
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
  Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Carver BS, et al. Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008. Cancer Cell. 2011. PMID: 21575859 Free PMC article.
• Persistent androgen receptor addiction in castration-resistant prostate cancer.
  Schweizer MT, Yu EY. Schweizer MT, et al. J Hematol Oncol. 2015 Nov 13;8:128. doi: 10.1186/s13045-015-0225-2. J Hematol Oncol. 2015. PMID: 26566796 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal